These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Clinical suppression of refractory ventricular tachycardia with oral bretylium not predicted by electrophysiologic drug testing.
    Author: Grubb BP, Luck JC, Bacaner M.
    Journal: Chest; 1988 Aug; 94(2):430-2. PubMed ID: 3396427.
    Abstract:
    We report the findings in a patient in whom intravenous bretylium was the only effective agent to suppress refractory ventricular tachycardia and ventricular fibrillation. After attempts to switch the patient to amiodarone and bethanidine (an oral analogue of bretylium) caused proarrhythmic effects, he was successfully converted to oral therapy with bretylium. Electrophysiologic testing was not predictive of the clinical response from oral bretylium. To our knowledge, this is the first report of a proarrhythmic effect from bethanadine and it suggests a divergence in the actions of various class 3 antiarrhythmic agents.
    [Abstract] [Full Text] [Related] [New Search]